Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 225Ac-FPI-2059 |
Synonyms | |
Therapy Description |
225Ac-FPI-2059 is a radiotherapy comprising the alpha radiation-emitting radionuclide actinium-225 linked to a molecule that targets NTSR1, which delivers radiation to NSTR1-expressing tumor cells, potentially leading to inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5045). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
225Ac-FPI-2059 | [225-Ac]-FPI-2059|Actinium Ac 225 FPI-2059 | 225Ac-FPI-2059 is a radiotherapy comprising the alpha radiation-emitting radionuclide actinium-225 linked to a molecule that targets NTSR1, which delivers radiation to NSTR1-expressing tumor cells, potentially leading to inhibition of tumor growth (Cancer Res (2023) 83 (7_Supplement): 5045). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05605522 | Phase I | 225Ac-FPI-2059 | A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours | Recruiting | USA | AUS | 0 |